{"id":"placebo-to-formoterol","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"2-5","effect":"Palpitations"},{"rate":"2-5","effect":"Muscle cramps"},{"rate":"2-5","effect":"Nervousness"},{"rate":"1-3","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL1256786","moleculeType":"Small molecule","molecularWeight":"344.41"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Formoterol activates beta-2 adrenergic receptors on bronchial smooth muscle cells, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained bronchodilation. This mechanism provides rapid onset (within minutes) and long duration of action (12+ hours), making it suitable for maintenance therapy in obstructive airway diseases. The drug also has anti-inflammatory effects on airway tissues.","oneSentence":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:35.936Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT06676319","phase":"PHASE2","title":"Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-11-07","conditions":"Asthma","enrollment":1147},{"nctId":"NCT07073950","phase":"PHASE4","title":"A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-24","conditions":"Chronic Obstructive Pulmonary Disease, Hyperinflation","enrollment":56},{"nctId":"NCT01577082","phase":"PHASE3","title":"Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-04-20","conditions":"Asthma","enrollment":542},{"nctId":"NCT06067828","phase":"PHASE3","title":"A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-10-24","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":171},{"nctId":"NCT07450482","phase":"PHASE2","title":"Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2025-07-22","conditions":"COPD (Chronic Obstructive Pulmonary Disease), COPD","enrollment":42},{"nctId":"NCT05888350","phase":"NA","title":"Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2023-04-01","conditions":"Cough","enrollment":502},{"nctId":"NCT07352488","phase":"NA","title":"Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2026-01-15","conditions":"Allergic Asthma","enrollment":400},{"nctId":"NCT06027606","phase":"PHASE1","title":"Cardiovascular Consequences of Inhaled Short-acting Beta-agonist Use","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2023-09-01","conditions":"Healthy","enrollment":81},{"nctId":"NCT03081156","phase":"PHASE4","title":"The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD","status":"COMPLETED","sponsor":"William Stringer, md","startDate":"2017-03-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":52},{"nctId":"NCT06075095","phase":"PHASE3","title":"A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-01-11","conditions":"COPD (Chronic Obstructive Pulmonary Disease)","enrollment":297},{"nctId":"NCT04193878","phase":"PHASE3","title":"ARrest RESpiraTory Failure From PNEUMONIA","status":"TERMINATED","sponsor":"Stanford University","startDate":"2020-06-01","conditions":"Pneumonia, Hypoxemia, Acute Respiratory Failure","enrollment":465},{"nctId":"NCT07114107","phase":"NA","title":"Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08","conditions":"Atopic Rhinitis, Atopic Asthma","enrollment":200},{"nctId":"NCT03022097","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-02-02","conditions":"COPD","enrollment":1625},{"nctId":"NCT05898984","phase":"PHASE1","title":"Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-04-24","conditions":"Asthma","enrollment":69},{"nctId":"NCT06105671","phase":"NA","title":"U-LABA/ICS Effects on Exercise Performance, Formoterol","status":"COMPLETED","sponsor":"Morten Hostrup, PhD","startDate":"2024-01-05","conditions":"Exercise Performance","enrollment":20},{"nctId":"NCT00383721","phase":"PHASE3","title":"Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1196},{"nctId":"NCT00383435","phase":"PHASE3","title":"Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1055},{"nctId":"NCT01803555","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2013-07-04","conditions":"Asthma","enrollment":605},{"nctId":"NCT05322707","phase":"PHASE3","title":"BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient","status":"COMPLETED","sponsor":"Cipla Ltd.","startDate":"2022-04-15","conditions":"Asthma","enrollment":1485},{"nctId":"NCT01108627","phase":"PHASE4","title":"Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists","status":"WITHDRAWN","sponsor":"Nemours Children's Clinic","startDate":"2010-10","conditions":"Safety of Long Acting Beta Agnoists","enrollment":""},{"nctId":"NCT00819637","phase":"PHASE4","title":"A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2009-01","conditions":"Acute Asthma","enrollment":2},{"nctId":"NCT05097014","phase":"PHASE4","title":"CHF5993 and CHF1535 pMDI on Lung Hyperinflation and Exercise Endurance Time in Subjects With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-10-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":106},{"nctId":"NCT03015259","phase":"PHASE3","title":"Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2016-12-29","conditions":"Asthma","enrollment":1762},{"nctId":"NCT04191434","phase":"PHASE3","title":"Efficacy and Safety of Flamboyant 125/12 Association in the Treatment of Adults With Moderate Asthma","status":"UNKNOWN","sponsor":"EMS","startDate":"2022-07-22","conditions":"Asthma","enrollment":134},{"nctId":"NCT04191447","phase":"PHASE3","title":"Efficacy and Safety of Flamboyant 200/12 Association in the Treatment of Adults With Severe Asthma","status":"UNKNOWN","sponsor":"EMS","startDate":"2022-07-22","conditions":"Asthma","enrollment":134},{"nctId":"NCT02573233","phase":"PHASE2","title":"Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-01-27","conditions":"Asthma","enrollment":42},{"nctId":"NCT03573817","phase":"PHASE3","title":"A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2018-05-31","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":122},{"nctId":"NCT01256086","phase":"PHASE2","title":"Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2010-12","conditions":"Asthma","enrollment":44},{"nctId":"NCT02227394","phase":"PHASE2","title":"Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2014-08","conditions":"Asthma, Asthma Chronic, Asthma Bronchial","enrollment":20},{"nctId":"NCT02000609","phase":"PHASE2","title":"A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of \"Nexthaler\" Dry Powder Inhaler in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2013-12","conditions":"COPD","enrollment":49},{"nctId":"NCT01738087","phase":"PHASE2","title":"Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-11","conditions":"Asthmatic","enrollment":30},{"nctId":"NCT01398111","phase":"PHASE1","title":"Pharmacokinetic Interaction Study of Glycopyrrolate and Formoterol in Healthy Volunteers","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-05","conditions":"COPD","enrollment":44},{"nctId":"NCT03468790","phase":"PHASE3","title":"Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.","status":"COMPLETED","sponsor":"Shanghai Biomabs Pharmaceutical Co., Ltd.","startDate":"2018-05-09","conditions":"Asthma, Allergic","enrollment":393},{"nctId":"NCT05055414","phase":"PHASE2","title":"Arformoterol/Budesonide for COVID-19","status":"UNKNOWN","sponsor":"Korea United Pharm. Inc.","startDate":"2021-11-01","conditions":"Coronavirus Infection","enrollment":140},{"nctId":"NCT03086460","phase":"PHASE2","title":"A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-09-08","conditions":"Asthma","enrollment":67},{"nctId":"NCT03590379","phase":"PHASE2","title":"Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2018-06-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":366},{"nctId":"NCT04616261","phase":"NA","title":"Beta2-adrenergic System and Training","status":"UNKNOWN","sponsor":"University of Copenhagen","startDate":"2020-11-10","conditions":"Healthy","enrollment":30},{"nctId":"NCT03478696","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":732},{"nctId":"NCT03478683","phase":"PHASE4","title":"A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":729},{"nctId":"NCT03565302","phase":"NA","title":"Beta2-adrenergic Agonism and Muscle Remodelling","status":"UNKNOWN","sponsor":"Morten Hostrup, PhD","startDate":"2018-06-25","conditions":"Hypertrophy, Physiologic Hypertrophy, Physical Activity","enrollment":72},{"nctId":"NCT04208581","phase":"PHASE3","title":"Yiqi Huoxue Huatan Granule for Reducing Mortality in COPD With Chronic Respiratory Failure","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2019-10-08","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Respiratory Failure","enrollment":372},{"nctId":"NCT02495168","phase":"PHASE3","title":"Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2017-01-13","conditions":"Asthma","enrollment":1714},{"nctId":"NCT02224157","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-28","conditions":"Asthma","enrollment":4215},{"nctId":"NCT02149199","phase":"PHASE3","title":"A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07-07","conditions":"Asthma","enrollment":3850},{"nctId":"NCT02685293","phase":"PHASE3","title":"Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD","status":"TERMINATED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2016-12-09","conditions":"COPD","enrollment":4},{"nctId":"NCT00773786","phase":"PHASE4","title":"Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Trinity Health Of New England","startDate":"2008-10","conditions":"COPD","enrollment":20},{"nctId":"NCT02048644","phase":"PHASE2","title":"Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2014-03","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":20},{"nctId":"NCT02429765","phase":"PHASE4","title":"Effect of Aclidinium/Formoterol on Nighttime Lung Function and Morning Symptoms in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Queen's University","startDate":"2015-10","conditions":"COPD","enrollment":40},{"nctId":"NCT00996697","phase":"PHASE4","title":"Differential Trough Effects of 'Triple Therapy' on Pulmonary Function in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2006-10","conditions":"COPD","enrollment":23},{"nctId":"NCT03104634","phase":"PHASE3","title":"The Effects of Inhaled Aclidinium Bromide/Formoterol Fumarate on Inspiratory Pleural Pressures in Smokers","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2017-05-01","conditions":"Smoking","enrollment":43},{"nctId":"NCT02643082","phase":"PHASE3","title":"A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-12-23","conditions":"COPD","enrollment":20},{"nctId":"NCT02291016","phase":"NA","title":"COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers","status":"COMPLETED","sponsor":"University of Tennessee Graduate School of Medicine","startDate":"2015-02","conditions":"COPD Exacerbation","enrollment":7},{"nctId":"NCT02343458","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-03-30","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1756},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT00995800","phase":"PHASE2","title":"Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2009-10","conditions":"Asthma","enrollment":46},{"nctId":"NCT02424344","phase":"PHASE4","title":"Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-04-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":267},{"nctId":"NCT03108534","phase":"PHASE2","title":"A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2017-02-28","conditions":"Asthma","enrollment":65},{"nctId":"NCT02533505","phase":"PHASE4","title":"Phase IV O2 Consumption Study in COPD Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-25","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":51},{"nctId":"NCT02347085","phase":"PHASE3","title":"24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-02-01","conditions":"COPD","enrollment":43},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT02796651","phase":"PHASE2","title":"Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-30","conditions":"Chronic Obstructive Pulmonary Disease - COPD","enrollment":132},{"nctId":"NCT02157935","phase":"PHASE3","title":"Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-27","conditions":"COPD Patients","enrollment":2026},{"nctId":"NCT01218399","phase":"NA","title":"Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-09","conditions":"Asthma","enrollment":10},{"nctId":"NCT01854047","phase":"PHASE2","title":"An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Asthma","enrollment":776},{"nctId":"NCT01488019","phase":"PHASE4","title":"Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)","status":"COMPLETED","sponsor":"Dey","startDate":"2012-03","conditions":"COPD","enrollment":1071},{"nctId":"NCT00706914","phase":"PHASE2","title":"Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2008-06-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":156},{"nctId":"NCT01085045","phase":"PHASE2","title":"Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2010-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":118},{"nctId":"NCT01572792","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-04","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":921},{"nctId":"NCT02165826","phase":"PHASE3","title":"Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1323},{"nctId":"NCT02347072","phase":"PHASE3","title":"24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2015-02-01","conditions":"COPD","enrollment":80},{"nctId":"NCT01344655","phase":"PHASE4","title":"Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT00868023","phase":"PHASE2","title":"Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-02","conditions":"Asthma","enrollment":69},{"nctId":"NCT02148120","phase":"PHASE2","title":"A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-04","conditions":"Asthma","enrollment":60},{"nctId":"NCT01584492","phase":"PHASE2","title":"Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-12","conditions":"Asthma","enrollment":59},{"nctId":"NCT01854645","phase":"PHASE3","title":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2103},{"nctId":"NCT00443482","phase":"PHASE2","title":"Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-02","conditions":"Asthma","enrollment":50},{"nctId":"NCT01854658","phase":"PHASE3","title":"Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1615},{"nctId":"NCT01437397","phase":"PHASE3","title":"Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-09","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1692},{"nctId":"NCT01845025","phase":"PHASE4","title":"Study of Safety of Foradil in Patients With Persistent Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05","conditions":"Persistent Asthma","enrollment":827},{"nctId":"NCT01641081","phase":"PHASE2","title":"Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Asthma","enrollment":174},{"nctId":"NCT01049360","phase":"PHASE2","title":"Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":128},{"nctId":"NCT01078623","phase":"PHASE2","title":"Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-02","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":176},{"nctId":"NCT01462942","phase":"PHASE3","title":"Long-term Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":2443},{"nctId":"NCT01120093","phase":"PHASE2","title":"Efficacy and Safety of Three Doses of Aclidinium Bromide Compared to Placebo and to an Active Comparator in Chronic Obstructive Pulmonary Disease (COPD) Patients.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":79},{"nctId":"NCT00403637","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Asthma","enrollment":45},{"nctId":"NCT00626522","phase":"PHASE2","title":"Aclidinium/Formoterol Fixed Combination Dose Finding Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-02","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":808},{"nctId":"NCT01783821","phase":"PHASE2","title":"LIPS-B: Lung Injury Prevention Study With Budesonide and Beta","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-07","conditions":"Acute Respiratory Distress Syndrome (ARDS)","enrollment":61},{"nctId":"NCT02570425","phase":"NA","title":"Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices","status":"COMPLETED","sponsor":"Research in Real-Life Ltd","startDate":"2014-07","conditions":"Asthma","enrollment":516},{"nctId":"NCT01194479","phase":"NA","title":"Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.","status":"COMPLETED","sponsor":"Yale University","startDate":"2010-08","conditions":"Type 1 Diabetes","enrollment":14},{"nctId":"NCT02308098","phase":"PHASE3","title":"To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","startDate":"2014-12","conditions":"Asthma","enrollment":72},{"nctId":"NCT01650441","phase":"PHASE2","title":"Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2012-04","conditions":"Asthma","enrollment":31},{"nctId":"NCT02345993","phase":"PHASE4","title":"Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis","status":"UNKNOWN","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2015-01","conditions":"Asthma, Asthmatic Crisis","enrollment":120},{"nctId":"NCT02197975","phase":"PHASE1","title":"Randomized, Crossover Safety and Pharmacokinetics Study of PT010","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2014-08","conditions":"COPD","enrollment":20},{"nctId":"NCT02242240","phase":"PHASE2","title":"Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":95},{"nctId":"NCT01043601","phase":"PHASE2","title":"Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control","status":"WITHDRAWN","sponsor":"Pearl Therapeutics, Inc.","startDate":"2010-07","conditions":"COPD","enrollment":""},{"nctId":"NCT00793624","phase":"PHASE3","title":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-02","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":906},{"nctId":"NCT00796653","phase":"PHASE3","title":"Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":937},{"nctId":"NCT01013753","phase":"PHASE2","title":"A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-02","conditions":"Asthma","enrollment":198},{"nctId":"NCT00849095","phase":"PHASE3","title":"Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2009-04","conditions":"Asthma","enrollment":860},{"nctId":"NCT01574651","phase":"PHASE3","title":"The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":934}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":526,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Formoterol","genericName":"Placebo to Formoterol","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}